In this issue:
Emotional impacts of axSpA
Efficacy and safety of brepocitinib
Rate of undiagnosed psoriasis
Nutritional intake of r-axSpA patients
Prevalence of depressive symptoms
Validated measures and fibromyalgia in axSpA patients
Impacts of pain catastrophising
Impacts of TNF inhibitors on workability
Association between psychological burden and disease activity
Treatment responses from TNFis and anti-IL17 agents
Please login below to download this issue (PDF)